JO
SPRY icon

John Overdeck’s ARS Pharmaceuticals SPRY Stock Holding History

John Overdeck’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
+52,400
New +$451K ﹤0.01% 4284
2025
Q4 		– Sell
-72,177
Closed -$725K – 4410
2025
Q3 		$725K Buy
+72,177
New +$1.04M ﹤0.01% 2790
2025
Q2 		– Sell
-10,771
Closed -$135K – 3519
2025
Q1 		$135K Sell
10,771
-87,307
-89% -$1.05M ﹤0.01% 2919
2024
Q4 		$1.03M Sell
98,078
-115,987
-54% -$1.62M ﹤0.01% 2155
2024
Q3 		$3.1M Buy
214,065
+167,141
+356% +$1.99M 0.01% 1370
2024
Q2 		$399K Buy
46,924
+26,507
+130% +$235K ﹤0.01% 2470
2024
Q1 		$209K Sell
20,417
-41,308
-67% -$308K ﹤0.01% 2699
2023
Q4 		$338K Buy
61,725
+8,878
+17% +$38.9K ﹤0.01% 2645
2023
Q3 		$200K Sell
52,847
-538,935
-91% -$3.54M ﹤0.01% 2641
2023
Q2 		$3.96M Buy
591,782
+479,801
+428% +$3.2M 0.01% 1033
2023
Q1 		$729K Buy
111,981
+10,835
+11% +$83.2K ﹤0.01% 2035
2022
Q4 		$863K Sell
101,146
-15,654
-13% -$102K ﹤0.01% 1773
2022
Q3 		$617K Sell
116,800
-76,700
-40% -$378K ﹤0.01% 1680
2022
Q2 		$820K Sell
193,500
-207,676
-52% -$724K ﹤0.01% 1625
2022
Q1 		$1.41M Buy
401,176
+9,492
+2% +$41.3K ﹤0.01% 1518
2021
Q4 		$2.61M Buy
391,684
+241,112
+160% +$1.96M 0.01% 1687
2021
Q3 		$1.5M Buy
+150,572
New +$3.71M ﹤0.01% 2240

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

John Overdeck's SPRY Position: Q2 2026 in Review

John Overdeck opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 52,400 shares worth $420K. The stake represents ﹤0.01% of the portfolio and ranks #4284 among its holdings. This is a return to the name: John Overdeck previously reported a position in SPRY as recently as Q3 2025.

John Overdeck first reported a position in SPRY in Q3 2021 and has held it in 17 quarters since. The position peaked at $3.96M in Q2 2023. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • John Overdeck held 52,400 shares of ARS Pharmaceuticals worth $420K as of Q2 2026.
  • ARS Pharmaceuticals was a new John Overdeck position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4284 holding.
  • John Overdeck first reported a position in ARS Pharmaceuticals in Q3 2021 and has held it in 17 quarters since.
  • John Overdeck's ARS Pharmaceuticals position peaked at $3.96M in Q2 2023.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.